48 results about "Lipoxin" patented technology

Provided are an apolipoprotein E detection reagent and the use thereof. The reagent comprises at least one of an ApoE2 protein detection reagent, an ApoE3 protein detection reagent and an ApoE4 protein detection reagent. One of a capture antibody and a detection antibody used for detecting ApoE2 protein or ApoE4 protein is a specific monoclonal antibody, and the capture antibody and the detection antibody used for detecting ApoE3 are both specific monoclonal antibodies. Genotyping of ApoE and quantitative detection of different genotypes of proteins are performed on the basis of an immunological detection method. The detection method has the advantages of being simple, easy to operate, short in time and cheap. A genotype detection result is highly consistent with a fluorescence PCR result. Genotyping of ApoE (6 types) can be performed, which is used to replace the nucleic acid detection and guide medication, and clarify the correlation of the ApoE4 genotype homozygosity / heterozygosity and the protein concentration of ApoE4 with AD.

The disclosure provides methods of reducing the risk of a major adverse cardiovascular event (MACE) in a subject having previously experienced acute coronary syndrome (ACS) and for reducing risk of a MACE in a patient who is diagnosed with coronary artery disease and has blood high-sensitivity C- reactive (hs-CRP) of >2.0 mg / L. The methods include administering to the subject an anti-oxLDL antibody. The anti-oxLDL antibody may be administered to the subject alone or in combination with one or more additional therapeutic agents, such as one or more lipid lowering agents.

The invention discloses a group of pyemia specific biomarkers and application thereof, and belongs to the field of medical detection.The biomarkers are formed by combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H, according to the invention, seven core proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened from TMT proteomics of serum of a clinical hemorrhagic patient, and four more important proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are obtained by further screening the seven proteins in a hemorrhagic cell model and the clinical hemorrhagic patient. The four proteins are verified again in serum of a hemorrhagic mouse animal experiment and an expanded-scale clinical hemorrhagic patient, and the potential of the four core proteins as serum biomarkers for early diagnosis of hemorrhagic disease is determined.

The present invention relates to high density lipoprotein (HDL) or HDL mimetics for use in the prevention and / or treatment of graft-versus-host disease (GvHD) or cytokine release syndrome in a subject.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting apolipoprotein E4 and application of the monoclonal antibody combination. The combination comprises a monoclonal antibody 4E10 and a monoclonal antibody 3H7, and complementary determining region (CDR) sequences of the monoclonal antibody 4E10 and the monoclonal antibody 3H7 are shown as SEQ ID NO.1 to SEQ ID NO.12. In double-antibody sandwich ELISA, 4E10 is used as a coating antibody, 3H7 is used as a labeled antibody, APOE4 subtypes can be effectively recognized, high-specificity and high-sensitivity detection of APOE4 can be achieved, the detection limit reaches 100 pg / mL, and the kit is suitable for quantitative detection of APOE4 in samples such as serum and cerebrospinal fluid. The method provides a reliable immunological tool for early risk assessment of the Alzheimer's disease, and has important clinical application value.

Alzheimer's disease, the most common cause of dementia in older individuals, is a debilitating neurodegenerative disease for which there is currently no cure. In the past, AD could only be definitively diagnosed by brain biopsy or upon autopsy after a patient died. These methods, which demonstrate the presence of the characteristic plaque and tangle lesions in the brain, are still considered the gold standard for the pathological diagnoses of AD. However, in the clinical setting brain biopsy is rarely performed and diagnosis depends on a battery of neurological, psychometric and biochemical tests, including the measurement of biochemical markers such as the ApoE and tau proteins or the beta-amyloid peptide in cerebrospinal fluid and blood. The present invention discloses and describes panels of makers that are differentially expressed in the disease state relative to their expression in the normal state and, in particular, identifies and describes panels of makers associated with neurocognitive disorders. Such biomarker panel might have considerable value in triaging patients with early memory disorders to yet more specific but more invasive and costly approaches such as molecular markers in CSF and on PET imaging in clinical trials and possibly in clinical practice.

Provided are a method of assisting the detection of nonalcoholic steatohepatitis (NASH) and a method that is able to assist in determining the degree of progression of any condition associated with NASH, which are far less invasive than liver biopsy and include simple operations and are independent of the skills of technicians.The present invention provides a method of assisting the detection of nonalcoholic steatohepatitis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body. Also, the present invention provides a method of assisting in determining the degree of progression of at least one medical condition associated with nonalcoholic steatohepatitis, which medical condition(s) is(are) selected from the group consisting of fatty degeneration (steatosis), inflammation, ballooning degeneration, and fibrosis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body.

A compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereoisomer, solvate, hydrate, polymorph or isotope variant thereof, can promote the binding of lactolipoprotein 3A1 / 2A1, in which the definitions of the groups are as detailed in the description and claims. The invention also relates to pharmaceutical compositions containing the compounds of formula (I) and their use in clinical treatment. # imgabs0 #

The present invention relates to lactolipoprotein subfamily 2 member A1 (BTN2A1) binding peptides wherein the amino acid sequence comprises amino acids other than glutamic acid, such as tryptophan, at a position corresponding to position 22 shown in SEQ ID NO: 1; an amino acid other than arginine at a position corresponding to position 73 shown in SEQ ID NO: 1, such as tyrosine; and / or an amino acid other than threonine at a position corresponding to position 81 shown in SEQ ID NO: 1, such as histidine or tryptophan. The BTN2A1 binding peptide may be included in a (exogenous) immune receptor or an extracellular domain thereof, preferably a gamma delta T cell receptor or an extracellular domain thereof, more preferably a gamma 9 delta 2T cell receptor or an extracellular domain thereof. The invention relates, inter alia, to the use in the treatment, preferably in the treatment of cancer and / or infection, or in diagnostic methods.

The present invention relates to compositions and methods for regulating apolipoprotein (a) expression. Specifically, oligomeric compounds with conjugate groups targeting apolipoprotein (a) [apo (a)] are provided herein. In certain embodiments, the oligomeric compound targeting apo (a) is conjugated to N-acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo (a) for reducing apo (a) to treat, prevent or improve diseases, conditions or symptoms associated with apo (a) and / or Lp (a). Certain diseases, conditions or symptoms associated with apo (a) and / or Lp (a) include inflammatory, cardiovascular and / or metabolic diseases, conditions or symptoms. The conjugated oligomeric compounds disclosed herein can be used to treat the diseases, conditions or symptoms in individuals in need thereof.

The invention provides application of a mucolipoprotein transient receptor potential channel 1 as a target spot in preparation of a medicine for treating pulmonary arterial hypertension, and belongs to the technical field of biological medicine manufacturing. The invention relates to application of a mucolipoprotein transient receptor potential channel 1 (TRRP Mucipin1, TRPML1) as a target spot in preparation, development or screening of a medicine for treating pulmonary hypertension (PH), in particular to application of the medicine in preparation, development or screening of the medicine for treating the PH. The invention also provides application of a reagent 1 for up-regulating smooth muscle cell Mcoln1 gene and / or smooth muscle cell TRPML1 protein expression or a reagent 2 for improving smooth muscle cell TRPML1 protein activity in preparation of drugs for treating PH. Experiments show that the over-expressed TRPML1 in the smooth muscle affects the PH pulmonary vascular remodeling process and PH generation and development through autophagy regulation and control, and the purpose of PH treatment is achieved.

This application discloses the application of pyridostigmine in the preparation of drugs for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Validation was conducted using animal models of NAFLD induced by three different etiologies: methionine-choline deficiency diet, high-fat diet, and leptin gene knockout. Pyridostigmine significantly improved vagal nerve activity in the model animals (e.g., improving high-frequency and baroreflex sensitivity in heart rate variability), effectively corrected serum lipid metabolism disorders (reducing LDL cholesterol), alleviated hepatocyte damage (reducing ALT and AST), and at the histopathological level, reduced hepatic steatosis, decreased inflammatory cell infiltration, and inhibited collagen deposition, thereby achieving the prevention and treatment of NAFLD.

Disclosed herein are methods of disease treatments by administering to a subject in need thereof a pharmaceutical composition comprising gene editing compositions. The methods disclosed herein can provide durable in vivo editing of PCSK9. More particularly, the compositions disclosed herein are capable of in vivo editing PCSK9 gene in humans and reducing PCSK9 protein and LDL-C for a potentially transformative treatment of cardiovascular disease, the leading cause of death in the United States and world-wide. Various aspects of the compositions, use and preparation are disclosed, including clinically supported therapeutically effective and safe human dosing of the compositions.

Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.

The invention belongs to the technical field of disease detection and health examination, and particularly relates to an enzyme-linked immunosorbent assay method of apolipoprotein E and application of the apolipoprotein E in glaucoma diagnosis. A capture antibody used by the kit is 1D4, a heavy chain variable region of the capture antibody comprises HCDR1-3 as shown in SEQ ID NO: 4-6, and a light chain variable region of the capture antibody comprises LCDR1-3 as shown in SEQ ID NO: 1-3; a detection antibody used by the kit is 3A6, a heavy chain variable region of the detection antibody comprises HCDR1-3 as shown in SEQ ID NO: 12-14, and a light chain variable region of the detection antibody comprises LCDR1-3 as shown in SEQ ID NO: 9-11. The double-antibody sandwich ELISA detection kit for detecting ApoE4 provided by the invention has no cross reaction with other subtypes of ApoEs, the used monoclonal antibody has high sensitivity, the kit can be used for screening glaucoma in physical examination and ophthalmic examination of old people, and the screening result is counted and summarized to a health information system and a cloud platform for big data analysis, so that the health condition of a patient can be detected.

The present disclosure provides a technique for simply, rapidly, and visually detecting modified LDL or stimulating AGEs. The present disclosure also provides a device or kit for detecting or quantifying an abnormal type of a biomarker molecule by forming a conjugate with the biomarker molecule, the device or kit comprising a membrane for developing a sample by utilizing a capillary action, wherein the membrane comprises: a detection part including a binding agent for detection which binds specifically to the biomarker molecule or a competitor molecule thereof; and a control part including a binding agent for control which binds specifically to a binding molecule having conjugate-forming ability with the abnormal type of the biomarker molecule or a competitor molecule thereof, and the kit or device comprises a sample contact part and a metal colloid as portions of the membrane or separate elements.

The invention provides application of barley pest larva defatted protein powder in preparation of drugs for treating inflammatory bowel diseases. The invention belongs to the technical field of medicine, and by establishing a dextran sodium sulfate induced mouse IBD model and lavaging barley pest larva defatted protein powder, it is found that the traditional Chinese medicine composition can relieve IBD mouse colitis symptoms, restore colon length, relieve mucosal lesion, retain goblet cell and crypt structures, reduce inflammatory cell infiltration and down-regulate inflammatory cytokine expression; the compound is expected to play an important role in preparing medicines for treating inflammatory enteritis.

Methods and materials for preventing and modulating atherosclerosis. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and atherosclerosis. The use of such peptides in reducing atherosclerosis, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower LDL cholesterol. Methods and materials for detecting T-cells that express CD40 (Th40 cells). Methods and materials for preventing, modulating, reducing and / or reversing type 2 diabetes and auto-inflammatory disease. In particular, small peptides that are capable of interacting with CD40, thereby interfering with the ability of CD40 to interact with CD154, which impacts inflammation and type 2 diabetes. The use of such peptides in reducing type 2 diabetes, and in particular, the autoimmune inflammatory response that may be a driving factor thereof. The use of such short peptides to lower IL2, INFγ, and IL17a. The use of such peptides to increase glucose transport protein (GLUT4). Methods and materials for detecting T-cells that express CD40 (Th40 cells).

To provide an improved method for treating IdiopathicPulmonaryFibrosis (IPF).SOLUTION: The invention features a polypeptide comprising a variant of plasminogen-activator inhibitor-1 (PAI-1) having a reduced capacity to bind vitronectin, a reduced capacity to interact with the PAI-1 clearance receptor LDL-receptor-related-protein 1 (LRP1), and a capacity to efficiently inhibit neutrophil elastases in presence of neutrophil extracellular traps (NETs). In some embodiments, a polypeptide of the present invention comprises a PAI-1 variant optionally fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions characterized by aberrant neutrophil elastase activity (as an example, idiopathic pulmonary fibrosis).SELECTED DRAWING: Figure 1

Provided are antisense agents, RNAi agents, pharmaceutical compositions, and methods of use for reducing the amount or activity of PLP1 RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject. In certain embodiments, also provided herein are oligomeric compounds and oligomeric duplexes for reducing the amount or activity of proteolipid protein 1 (PLP1) RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a leukodystrophy. Such symptoms and hallmarks include hypotonia, nystagmus, optic atrophy, respiratory distress, delay in motor function development, cognitive dysfunction, speech dysfunction, spasticity, ataxia, seizures, choreiform movements, and death. Such leukodystrophies include Pelizaeus-Merzbacher disease.

Saikosaponin C and uses thereof as a modulator for vascular aging and arteriosclerosis resulting therefrom are disclosed. A composition containing Saikosaponin C as an active ingredient for treating, preventing, or alleviating age-related vascular diseases, diseases due to vascular aging, specifically, arteriosclerosis, or symptoms due to vascular aging are disclosed. The composition is expected to be of great use in the treatment, prevention, and alleviation of arteriosclerosis as a supplement, substitute, or combination of an existing arteriosclerosis treatment that lowers LDL-C.

Compounds of formula (I), or pharmaceutically acceptable salts, enantiomers, diastereoisomers, solvates, hydrates, polymorphs or isotopic variants thereof, can promote the binding of lactolipoproteins 3A1 / 2A1, where the definitions of the groups are as detailed in the description and claims, or pharmaceutically acceptable salts, enantiomers, diastereoisomers, solvates, hydrates, polymorphs or isotopic variants thereof. The invention also relates to pharmaceutical compositions containing the compounds of formula (I) and their use in clinical therapy. # imgabs0 #

The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a monohydric alcohol or an amide wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and / or strip and / or a contact lens.

The invention belongs to the technical field of biology, and particularly relates to a composite peptide capable of improving animal immunity and a preparation method of the composite peptide, and the composite peptide is formed by compounding InflamBlock-9 peptide and ImunoEnhance-7 peptide according to the mass ratio of 3: 1. Wherein the InflamBlock-9 peptide is used for reducing excessive secretion of proinflammatory factors IL-1beta, IL-6 and TNF-alpha through targeted inhibition of an NF-kappa B signal channel key protein Ikappa B kinase (IKK); the ImmunoEnhance-7 peptide is used for promoting the synthesis of immune globulins IgG (Immunoglobulin G) and IgA (Immunoglobulin A) and apolipoprotein A1 (Apo-A1) by activating a JAK-STAT (JavaScript Activated Amplification) signal channel. The combined use of the two can significantly reduce the levels (Plt, 0.05) of IL-1beta, IL-6 and SAA in the serum of cats in a stress state, improve the contents (Plt, 0.05 or Plt, 0.10) of IL-10, IgG and Apo-A1, and effectively relieve the inflammatory overexpression and improve the immunosuppression state. According to the preparation method, efficient preparation of the polypeptide is achieved through a prokaryotic and eukaryotic dual-expression system, the process is controllable, cost is low, and the preparation method is suitable for development of functional food or health care products for pets.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting apolipoprotein E4 and application thereof. The combination comprises monoclonal antibody 4E10 and monoclonal antibody 3H7, and the complementarity determining region (CDR) sequences thereof are shown as SEQ ID NO. 1 to SEQ ID NO. 12. In a double antibody sandwich ELISA, 4E10 is used as a coating antibody, and 3H7 is used as a labeled antibody, so that APOE4 subtypes can be effectively recognized, high specificity and high sensitivity detection of APOE4 can be realized, the detection limit reaches 100 pg / mL, and the method is suitable for quantitative detection of APOE4 in serum, cerebrospinal fluid and the like. The method provides a reliable immunological tool for early risk assessment of Alzheimer's disease, and has important clinical application value.

Provided herein, among other things, are novel and improved glycoproteins, including modified glycoproteins; engineered viral particles comprising such novel and modified glycoproteins; and methods for targeted delivery, for example, to immune cells such as T cells. In some aspects, the engineered viral particles allow targeted delivery of the cargo for various applications, including treating various conditions such as autoimmune diseases and cancer. In some aspects, the engineered viral particles comprise a viral fusogen that is a glycoprotein of Chandipura, Perinet, Piry, Jurona viruses, or variants thereof. In other aspects, the engineered viral particles comprise a modified vesiculovirus glycoprotein mutant, for example, with mutations at amino acids corresponding to positions I347 or R354 of Vesicular Stomatitis Virus G (VSV-G) that reduce binding to Low Density Lipoprotein Receptor (LDL-R).

To provide methods and compositions for preventing or treating cognitive decline associated with dementia and / or mild cognitive impairment and / or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG / heparin binding affinities of ApoE.SOLUTION: Provided is an Fc fusion protein comprising an Fc region of an antibody fused to a polypeptide comprising an HSPG-binding domain of wild-type ApoE or mutant ApoE, the HSPG-binding domain comprising a specific amino acid sequence.SELECTED DRAWING: Figure 1

The application discloses an enzyme response type composite scaffold for muscle injury repair and a preparation method thereof, and belongs to the technical field of polymer scaffolds. The application takes a decellularized matrix as the scaffold, and combines with MMP-2 responsive nanomicelles loaded with lipoxin LxA4 and SDF-1 alpha, so that precise and long-acting release of drugs at the injury site is realized. Through the synergistic effect of LxA4 and SDF-1 alpha, the inflammatory reaction at the injury site is reduced, and the recruitment and migration of endogenous stem cells are enhanced, so that the repair cycle is shortened. In addition, the composite scaffold of the application also ensures the synchronism of the degradation speed of the scaffold and the tissue regeneration speed, and ensures the effective support of the scaffold in the tissue healing process. The application provides a safer and more effective solution for the treatment of muscle tissue defects, and promotes the application of tissue engineering in clinical practice.

A method of preventing or treating or controlling a respiratory disease in a bovine by delivering to a lung or trachea of the bovine a composition including a polyplex having one or more mRNA encoded with a molecule selected from lycosylphosphatidylinositol (GPI) complex, antibody immunoglobulin G (IgG), antibody immunoglobulin A (IgA), antibody immunoglobulin M (IgM), antimicrobial peptide Bactenecin 5 (Bac5), antimicrobial peptide Bactenecin 7 (Bac7), bovine myeloid antimicrobial peptide (BMAP-28), lipoxin inducing enzymes, resolvin inducing enzymes, cytokines, CRISPR associated protein 13 (Cas13) enzymes, nanoluciferase (NLuc) proteins, and gene activator, catalytically dead CRISPR-associated protein 9 fused to an activator selected from the group consisting of VP64-p65-Rta transactivation domain (dCas9-VPR), VP64, and VP64-p65-HSF1 on the N terminus and SS18 on the C-terminus, and a polymer prepared by polymerizing a diacrylate monomer; one or more linker monomers; and one or more branching monomers; and end-capping the polymer.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLP1 RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a leukodystrophy. Such symptoms and hallmarks include hypotonia, nystagmus, optic atrophy, respiratory distress, motor delays, cognitive dysfunction, speech dysfunction, spasticity, ataxia, seizures, choreiform movements, and death. Such leukodystrophies include Pelizaeus-Merzbacher disease.